The purpose of this research study is to compare the effects of ALTO-100, the study’s investigational drug, versus placebo (an inactive substance) in treating symptoms of depression in participants who have Bipolar Disorder with depression (BD-D) and who are also taking mood stabilizers and/or an atypical antipsychotic.
The study will last approximately 3 to 4 months, consisting of a screening period (about 6 weeks), followed by a 6-week double-blind treatment period where you may receive ALTO-100 or placebo. If you complete the double-blind treatment period, you will be given the option to enter a 7-week open-label period where you are guaranteed to receive ALTO 100. Eligible participants will receive study-related care and evaluations at no cost. Compensation for your time and travel may be available.
